A pharmacokinetic and safety study of BIIB132 in adults with spinocerebellar ataxia 3
| ISRCTN | ISRCTN94357046 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN94357046 |
| EudraCT/CTIS number | 2021-002223-37 |
| IRAS number | 1004052 |
| Secondary identifying numbers | 260SA101, IRAS 1004052, CPMS 50391 |
- Submission date
- 19/02/2022
- Registration date
- 05/05/2022
- Last edited
- 07/06/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Plain English summary of protocol
Background and study aims
Spinocerebellar ataxia 3 (SCA3) is a rare, autosomal mainly inherited (a condition can be passed down from parent to child) neurodegenerative disorder, and currently no specific approved therapy is available to slow clinical progression.
This is a Phase I, first in human, blinded (participant and doctor will not know which medication will be given) study where participants will be randomly assigned to either the study drug, i.e. BIIB132, or placebo (looks like the study drug but contains no active ingredient). This study is being carried out to find out more about the study drug, BIIB067 as a potential treatment for people with SCA3.
Who can participate?
Adult participants (aged 18 years and over) diagnosed with spinocerebellar ataxia 3 (SCA3)
What does the study involve?
Potential participants will be screened to assess their eligibility to enter the study within 6 weeks before the dose administration. If a potential participant is eligible to take part in the study, he/she will enter the treatment period for that group, also called “cohort”, to which participants will be assigned randomly (by chance).
This study will have five cohorts, and each cohort will test a different dose of the study drug. The frequency of study treatment administration is projected to be every 4 weeks (total of 4 doses) for participants in Cohorts 1 to 4 and every 4 weeks (total of 4 doses), every 8 weeks (total of 2 doses), or every 12 weeks (total of 2 doses) for participants in Cohort 5. However, dose levels and frequency of administration may be revised based on the safety data from previous cohorts.
The study medication is given intrathecally (by an injection into the spinal canal). The total study duration for each participant will be up to 44 weeks.
What are the possible benefits and risks of participating?
There might be no direct benefit from taking part in the study. Since BIIB132 has not yet been tested in humans, the possible side effects are not known; however, as with other medicines, it is possible that BIIB132 may cause adverse reactions.
Where is the study run from?
The study sites are all hospital-based specialist ataxia centres
When is the study starting and how long is it expected to run for?
February 2022 to March 2025
Who is funding the study?
Biogen Idec Research Limited (UK)
Who is the main contact?
clinicaltrials@biogen.com
Contact information
Principal Investigator
250 Euston Road
London
WC1 2PG
United Kingdom
| Phone | +44 (0)203 448 3141 |
|---|---|
| p.giunti@ucl.ac.uk |
Study information
| Study design | Randomized double-blind placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | A Phase I, blinded, randomized, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of multiple ascending doses of BIIB132 administered intrathecally to adults with spinocerebellar ataxia 3 |
| Study objectives | 1. To evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia 3 (SCA3) 2. To characterize the multiple-dose pharmacokinetics (PK) of BIIB132 administered via IT injection to participants with SCA3 |
| Ethics approval(s) | Approved 13/04/2022, East of England - Cambridgeshire and Hertfordshire Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)20 710 48096; cambsandherts.rec@hra.nhs.uk), ref: 22/EE/0059 |
| Health condition(s) or problem(s) studied | Spinocerebellar ataxia 3 |
| Intervention | Randomisation process: Interactive Response Technology (IRT) Study arms: Experimental: BIIB132: Dose 1 Participants will receive BIIB132, Dose 1, intrathecally (IT), every 4 weeks (Q4W), up to Day 85. Experimental: BIIB132: Dose 2 Participants will receive BIIB132, Dose 2, IT, Q4W, up to Day 85. Experimental: BIIB132: Dose 3 Participants will receive BIIB132, Dose 3, IT, Q4W, up to Day 85. Experimental: BIIB132: Dose 4 Participants will receive BIIB132, Dose 4, IT, Q4W, up to Day 85. Experimental: BIIB132: Dose 5 Participants will receive BIIB132, Dose 5, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57. Placebo Comparator: BIIB132-Matching Placebo: Doses 1 to 5 Participants will receive a BIIB132-matching placebo of Doses 1 to 4, IT, Q4W, up to Day 85 and a BIIB132-matching placebo of Dose 5, IT, either Q4W or Q12W, up to Day 85 or Q8W, up to Day 57. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | BIIB132 |
| Primary outcome measure | 1. Number of participants with adverse events (AEs) assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE, Version 5) from Day 1 to Day 267 2. Number of participants with serious adverse events (SAEs) assessed using National Cancer Institute CTCAE, Version 5 from Screening to Day 267 |
| Secondary outcome measures | 1. Area under the concentration-time curve (AUC) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 2. Area under the concentration versus time curve, from time of dosing (time = 0) to infinity (AUCinf) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 3. Area under the concentration versus time curve, from time of dosing (time = 0) to time of the last measurable effect (AUClast) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 4. Maximum observed concentration (Cmax) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 5. Time to reach maximum observed concentration (Tmax) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 6. Elimination half-life (t½) of BIIB132 measured using serum samples at pre-dose and multiple timepoints post-dose on Day 1 up to Day 85 |
| Overall study start date | 16/02/2022 |
| Completion date | 31/03/2025 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Both |
| Target number of participants | 48 |
| Key inclusion criteria | 1. Diagnosis of SCA3 with CAG repeats ≥60 in ATXN3 gene 2. Symptomatic ataxia with a screening Scale for Assessment and Rating of Ataxia (SARA) score 3 to 15 (still ambulatory) and a minimum SARA gait subscore of 1 3. Able to ambulate 8 m independently without any assistive device 4. Treatment naïve or on a stable dose of symptomatic therapy for a minimum of 4 weeks prior to screening |
| Key exclusion criteria | 1. Unstable psychiatric illness or untreated major depression within 90 days before screening 2. History or screening magnetic resonance imaging (MRI) results show evidence of structural abnormalities that couldcontribute to the participant’s clinical state other than findings typical of SCA3 or any finding that might pose a risk to the participant 3. MRI brain findings of prior cerebellar stroke or clinical stroke within 12 months before screening 4. History of brain surgery regardless of purpose 5. Any contraindications to undergoing brain MRI 6. History of, or ongoing, malignant disease, (with the exception of basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 12 months prior to screening). Participants with cancers in remission for longer than 5 years may be included 7. History of epilepsy or the occurrence of seizures within 3 years prior to screening 8. Evidence of untreated/unstable thyroid disease 9. Poorly controlled diabetes mellitus 10. History of alcohol or substance abuse within the past year prior to screening 11. Use of off-label drugs for ataxia within 4 weeks prior to screening 12. Prior enrollment in any interventional clinical study in which an investigational treatment or approved therapy forinvestigational use is administered within 5 half-lives or 3 months, whichever is longer, prior to the screening visit 13. Any antiplatelet (except for aspirin up to 100 mg/day) or anticoagulant medication that cannot be safely interrupted for a lumbar puncture (LP) procedure 14. Any contraindications to LP procedures 15. Participants who are pregnant or currently breastfeeding and those intending to become pregnant during the study 16. Prior enrollment in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months prior to screening visit Note: other protocol-defined inclusion/exclusion criteria may apply |
| Date of first enrolment | 17/12/2021 |
| Date of final enrolment | 31/03/2025 |
Locations
Countries of recruitment
- England
- France
- Germany
- Israel
- Netherlands
- Portugal
- United Kingdom
Study participating centres
London
WC1N 3BG
United Kingdom
Headington
Oxford
OX3 9DU
United Kingdom
Sponsor information
Industry
Innovation House
70 Norden Road
Maidenhead
SL6 4AY
England
United Kingdom
| clinicaltrials@biogen.com |
Funders
Funder type
Industry
Private sector organisation / For-profit companies (industry)
- Location
- United States of America
Results and Publications
| Intention to publish date | 31/12/2025 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | 1. Peer-reviewed scientific journals 2. Conference presentation 3. Submission to regulatory authorities 4. Other Throughout the study, subject data will be identified only by a subject identification number. Personal data will be blinded in all clinical data analyses. Authorised Sponsor personnel, including study monitors, auditors, other relevant parties and health regulatory agencies will have access to personal medical data to ensure a high-quality standard for the study. |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are/will be available upon request. For general enquiries, please contact DataSharing@Biogen.com. The data to be shared is the individual participant data collected during the trial, which supports the research proposal, after anonymization and upon approval of the research proposal, along with Study Protocols and Clinical Study Reports. Data will be available 18 months after study completion and post US and EU marketing approvals, with no end date. The data will be shared with qualified scientific researchers who provide a methodologically sound proposal to achieve the objectives in the approved proposal. Proposals should be submitted through Vivli (https://vivli.org). To gain access, data requestors will need to sign a data-sharing agreement. Data are made available for 1 year on a secure platform. Exceptions to Biogen's Data Sharing Policy: 1. Clinical trials where there is a reasonable likelihood that the study participant could be re-identified, such as with trials of rare diseases and single-center studies. 2. Clinical trials where data sharing is prohibited by the informed consent; or where regulatory, legal, contractual, or other limitations exist. 3. Clinical trials where data/documents are not in English. 4. Clinical trials where there are ongoing regulatory activities or publication plans. Imaging data (e.g. DICOM files of images from x-rays, ultrasounds, MRI scans, etc) is not generally shared and genomic data is only shared with explicit consent. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
07/06/2022: Internal review.
14/04/2022: ISRCTN received notification of combined HRA/MHRA approval for this trial on 14/04/2022.
21/02/2022: Trial's existence confirmed by the HRA.
